Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the the potential of I apamistamab(Iomab-B) and it's P3 SIERRA Trial of Iomab-B in elderly patients with active relapsed or refractory AML

Ticker(s): ATNM

Who's the expert?

Institution: Guys Hospital, London

Emeritus Professor of Hematology at Nottingham and Consultant in Hematology at Guy's and St Thomas' Hospital, London.
Current work focuses on the integration of new agents into the treatment pathway and the use of MRD analysis for risk stratification in AML
Chief Investigator of the ongoing NCRI AML18 and AML19 trial' has published over 300 papers in the field of AML and allogeneic transplantation.

Interview Goal

This conversation will focus on the potential of I apamistamab(Iomab-B), a monoclonal antibody that is connected to radioactive material which delivers radiation preferentially to the bone marrow and spleen to help patients get ready for bone marrow transplant. We will dig into the positive top-line results from pivotal Phase 3 SIERRA Trial of Iomab-B in elderly patients with active relapsed or refractory AML.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.